Virtual Meetings 2022

Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

For up-to-date schedule of upcoming sessions in this series, please click here.

PARTICIPATING FACULTY

Pasi A Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Joel W Neal, MD, PhD
Associate Professor of Medicine
Division of Oncology, Department of Medicine
Stanford Cancer Institute
Stanford University
Palo Alto, California



Lecia V Sequist, MD, MPH
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital Cancer Center
The Landry Family Professor of Medicine
Harvard Medical School
Boston, Massachusetts

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for non-small cell lung cancer with an EGFR mutation. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Therapeutic Selection for Patients with Localized Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation

    MODULE 2: Current and Future Management of Metastatic NSCLC with an EGFR Mutation

    MODULE 3: Available Therapeutic Strategies for Patients with NSCLC Harboring an EGFR Exon 20 Insertion Mutation

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of non-small cell lung cancer with an EGFR mutation.

Learning Objectives

  • Evaluate the various oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain and determine how these may predict potential response or lack thereof to currently available EGFR-directed therapies.
  • Acknowledge the FDA approval of adjuvant osimertinib for localized non-small cell lung cancer (NSCLC) with an EGFR mutation, and identify patients for whom this novel treatment approach would be warranted.
  • Evaluate published clinical trial findings supporting the use of osimertinib and erlotinib/ramucirumab as first-line therapy for patients with metastatic NSCLC harboring an actionable EGFR mutation, and consider the effect of this information on current and future clinical practice.
  • Develop an optimal approach to the management of NSCLC with an EGFR mutation and central nervous system metastases, considering the implications of symptomatology, number of lesions and other factors.
  • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors (TKIs), and discern how available and investigational therapies can be optimally employed in the protocol and nonresearch care of patients with progressive disease.
  • Evaluate the mechanism of action and published research data with the dual-targeting EGFR-MET bispecific antibody amivantamab and the novel EGFR TKI mobocertinib for NSCLC with an EGFR exon 20 insertion mutation, and consider how these therapies fit into current clinical management algorithms.
  • Recall the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for NSCLC with an EGFR mutation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr JänneConsulting Agreements: AbbVie Inc, ACEA Biosciences Inc, Accutar Biotech, Allorion Therapeutics, Araxes Pharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Ignyta Inc, Kura Oncology, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics, Novartis, Nuvalent, Pfizer Inc, Sanofi Genzyme, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Transcenta, Voronoi; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Puma Biotechnology Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc; Patents, Royalties: LabCorp for post-marketing royalties from Dana-Farber Cancer Institute owned intellectual property on EGFR mutations licensed to Lab Corp; Stock Options/Ownership — Public Ineligible Company: Gatekeeper Pharmaceuticals. Dr NealAdvisory and Consulting Roles: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Calithera Biosciences, D2G Oncology Inc, Exelixis Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Jounce Therapeutics, Lilly, Natera Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Surface Oncology, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Nektar, Novartis, Takeda Pharmaceuticals USA Inc. Dr SequistAdvisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.

SURVEY PARTICIPANTSDavid Planchard, MD, PhDAdvisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Samsung Bioepis. Gregory J Riely, MD, PhDContracted Research: Genentech, a member of the Roche Group, Lilly, Merck, Mirati Therapeutics, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Novartis.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.